Minimal residual disease (MRD) monitoring is a promising and controversial topic, with its increasing use in clinical trials being followed acutely. Speaking from the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA, Farhad Ravandi, MD, from the University of Texas MD Anderson Cancer Center, Houston, TX, highlights studies of acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) which are monitoring MRD.
